MOH INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Molina Healthcare, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit

Core Viewpoint - The Molina Healthcare class action lawsuit alleges that the company and its executives failed to disclose critical information regarding financial performance and medical cost trends, leading to significant stock price declines during the class period [1][3][4]. Summary by Sections Class Action Details - The class action lawsuit is titled Hindlemann v. Molina Healthcare, Inc., and covers purchasers of Molina Healthcare securities from February 5, 2025, to July 23, 2025, with a deadline of December 2, 2025, for lead plaintiff applications [1][2]. Allegations Against Molina Healthcare - The lawsuit claims that Molina Healthcare did not disclose adverse facts about its medical cost trend assumptions, the dislocation between premium rates and medical costs, and the dependency of near-term growth on low utilization of various health services [3]. - It is alleged that Molina Healthcare's financial guidance for fiscal year 2025 was likely to be cut due to these undisclosed issues [3]. Financial Performance and Stock Impact - On July 7, 2025, Molina Healthcare reported adjusted earnings of approximately $5.50 per share, which was below prior expectations due to medical cost pressures across all business lines, leading to a 10.2% cut in earnings guidance [4]. - Following the financial results announcement on July 23, 2025, Molina Healthcare reported GAAP net income of $4.75 per diluted share for Q2 2025, an 8% decrease year-over-year, and revised its full-year 2025 adjusted earnings expectation to no less than $19.00 per diluted share, resulting in a nearly 17% drop in stock price [5]. Lead Plaintiff Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Molina Healthcare securities during the class period to seek lead plaintiff status, which involves directing the class action lawsuit on behalf of all class members [6]. About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone, and is recognized for securing significant monetary relief for investors [7][8].